BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity

Hormones and Cancer - United States
doi 10.1007/s12672-014-0207-9
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Real‐World Toxicity Experience With BRAF/MEK Inhibitors in Patients With Erdheim‐Chester Disease

Oncologist
Cancer ResearchMedicineOncology
2019English

Prognostic Utility of BRAF Mutation in Papillary Thyroid Cancer

Molecular and Cellular Endocrinology
BiochemistryEndocrinologyMolecular Biology
2010English

General Review of Titanium Toxicity

International Journal of Implant Dentistry
2019English

Tyrosine Kinase Inhibitors in Advanced Thyroid Cancer

Journal of the Siena Academy of Sciences
2012English

Thyroid Stimulating Hormone Increases Iodine Uptake by Thyroid Cancer Cells During BRAF Silencing

Journal of Surgical Research
Surgery
2013English

Surgical Tactics Optimization for Treatment of BRAF Positive Papillary Thyroid Cancer

Clinical and experimental thyroidology
2018English

The Evolving Field of Kinase Inhibitors in Thyroid Cancer

Critical Reviews in Oncology/Hematology
GerontologyGeriatricsHematologyOncology
2015English

Financial Toxicity in Thyroid Cancer—An Analysis From the North American Thyroid Cancer Survivorship Study

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2016English

Tumorigenesis of Papillary Thyroid Cancer Is Not BRAF-Dependent in Patients With Acromegaly

PLoS ONE
Multidisciplinary
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy